CTAD: TauRx Touts Safety Profile as Anavex Stumbles over Data Discrepency

 As the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference continues, TauRx Pharmaceuticals and Anavex Life Sciences presented positive data from their alternatives to the anti-amyloid approach. 

TauRx's Oral Candidate Shows Strong Safety Profile

Based in Scotland and Singapore, TauRx is developing hydromethylthionine mesylate (HMTM), which targets Tau pathology in Alzheimer’s. While patients on Biogen's Aduhelm face bi-weekly injections, HMTM is an oral candidate with a strong safety profile.

Phase III data released in October showed HMTM significantly slowed cognitive and brain atrophy compared to historical controls, TauRx reported. The company faced challenges with the placebo group, so data from publicly available placebo arms from other AD trials were used to prove efficacy.

During its CTAD presentation, TauRx shared topline data from the trial that showed sustained improvement in cognition over 18 months over pre-treatment levels in participants with mild cognitive impairment.

According to the press release, “sustained cognitive improvement over baseline has not been seen with any other late-stage treatment for Alzheimer's currently being studied.”

A data scrape by the Alzheimer’s Association in January showed 143 agents currently in clinical trials for AD.

A unique aspect of HMTM is its safety profile. The drug showed no risk of amyloid-related imaging abnormalities (ARIA), a side effect seen in nearly 40% of AD patients taking Aduhelm in Biogen’s Phase III studies.

Armed with efficacy data, a robust safety profile and convenient oral dosing, TauRx is prepping for regulatory submissions in the U.K., U.S. and Canada.

Anavex's Positive Data Marred by Mathematical Slip

Anavex is attempting to treat the mild cognitive impairment associated with Alzheimer's disease via a small molecule activator of the sigma-1 receptor (SIGMAR1).

Research suggests SIGMAR1 is pivotal to promoting neuroplasticity and restoring homeostasis in neural cells.

Anavex announced that patients treated with its SIGMAR1 activator, ANAVEX2-73 (blarcamesine), were 84% more likely to have improved cognition scores of –0.50 points or better compared to patients on placebo. On average, the patients who saw gains showed improvement of    –4.03 points, a difference considered significant.

However, Anavex is facing some suspicion over trial results. In its press release, the biopharma reported the drug led to a 45% slower rate of decline compared to placebo patients. But Investor’s Business Daily reported that a math error in the CTAD presentation indicated the drug may have slowed cognition by 33% instead.

According to Edward Hammond, CMO of Anavex, the company plans to “discuss these findings with regulatory authorities in the context of the ongoing clinical development of ANAVEX 2-73 in this indication."

BioSpace has reached out to Anavex for further comment.  

https://www.biospace.com/article/ctad-taurx-touts-safety-and-efficacy-as-anavex-stumbles-over-potential-data-error/